Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (2s,5r)-7-oxo-n-(4-piperidinyl)-6-(sulfooxy)-1,6-diazabicyclo(3.2.1)octane-2-carboxamide
2. Mk-7655
3. Mk7655
4. Relebactam Anhydrous
1. 1174018-99-5
2. Mk-7655
3. Relebactam Anhydrous
4. Relebactam [inn]
5. (-)-relebactam Anhydrous
6. 1oqf7tt3pf
7. Chembl3112741
8. Mk-7655a
9. Mk7655
10. Sulfuric Acid Mono-((2s,5r)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diaza-bicyclo(3.2.1)oct-6-yl) Ester
11. (1r,2s,5r)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl Hydrogen Sulfate
12. [(2s,5r)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl] Hydrogen Sulfate
13. Unii-1oqf7tt3pf
14. Relebactam [mi]
15. Relebactam [who-dd]
16. Bdbm1858
17. Schembl3721178
18. Gtpl10852
19. Ex-a864
20. Sulfuric Acid Mono-[7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diaza-bicyclo[3.2.1]oct-6-yl] Ester
21. Bdbm50447651
22. Mfcd28502833
23. Zinc43206319
24. Cs-5391
25. Db12377
26. Ac-36163
27. As-35205
28. Br163749
29. Hy-16752
30. Us8487073, 1a
31. S0074
32. J3.628.086g
33. Mk-7655;mk7655;mk 7655
34. J-690043
35. Q27252695
36. (2s,5r)-7-oxo-n-piperidin-4-yl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
Molecular Weight | 348.38 g/mol |
---|---|
Molecular Formula | C12H20N4O6S |
XLogP3 | -3.6 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 4 |
Exact Mass | 348.11035554 g/mol |
Monoisotopic Mass | 348.11035554 g/mol |
Topological Polar Surface Area | 137 Ų |
Heavy Atom Count | 23 |
Formal Charge | 0 |
Complexity | 585 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Relebactam is indicated in combination with [imipenem] and [cilastatin] for the treatment of complicated urinary tract infections (including pyelonephritis), and complicated intra-abdominal infections caused by susceptible organisms in adults.
Relebactam prevents the hydrolysis of [imipenem], allowing it to exert its bactericidal effect.
beta-Lactamase Inhibitors
Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES. (See all compounds classified as beta-Lactamase Inhibitors.)
Absorption
Currently, relebactam is only available as an intravenous product; therefore, there is no relevant absorption data in the literature.
Route of Elimination
Approximately 90-100% of relebactam is renally eliminated.
Volume of Distribution
Relebactam has a volume of distribution of approximately 19 L with both single and steady state dosing.
Clearance
Relebactam has a reported total clearance of approximately 130-150 mL/min (8 L/h). About 30% of the total drug clearance can be attributed to active tubular secretion.
Relebactam does not undergo significant metabolism and can be found mostly unchanged in human plasma.
Relebactam has a half-life of 1.2 hours as per official FDA labeling. Values reported in pharmacokinetic studies vary from 1.35-1.8 hours.
Relebactam is a beta-lactamase inhibitor known to inhibit many types of beta-lactamases including Ambler class A and Ambler class C enzymes, helping to prevent [imipenem] from degrading in the body. Similar to the structurally-related [avibactam], first, relebactam binds non-covalently to a beta-lactamase binding site, then, it covalently acylates the serine residue in the active site of the enzyme. In contrast to some other beta-lactamase inhibitors, once relebactam de-acylates from the active site, it can reform it's 5 membered ring and is capable of rebinding to target enzymes.
NDC Package Code : 24823-154
Start Marketing Date : 2019-01-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
Patents & EXCLUSIVITIES
Patent Expiration Date : 2033-03-21
CILASTATIN SODIUM; IMIPENEM; RELEBACTAM
US Patent Number : 8487093
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 212819
Patent Use Code : U-2587
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2033-03-21
Patent Expiration Date : 2033-03-21
CILASTATIN SODIUM; IMIPENEM; RELEBACTAM
US Patent Number : 8487093
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 212819
Patent Use Code : U-2840
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2033-03-21
Patent Expiration Date : 2033-03-21
CILASTATIN SODIUM; IMIPENEM; RELEBACTAM
US Patent Number : 8487093
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 212819
Patent Use Code : U-2586
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2033-03-21
CILASTATIN SODIUM; IMIPENEM; RELEBACTAM
Exclusivity Code : NCE
Exclusivity Expiration Date : 2024-07-16
Application Number : 212819
Product Number : 1
Exclusivity Details :
CILASTATIN SODIUM; IMIPENEM; RELEBACTAM
Exclusivity Code : GAIN
Exclusivity Expiration Date : 2029-07-16
Application Number : 212819
Product Number : 1
Exclusivity Details :
ABOUT THIS PAGE
A Relebactam anhydrous manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Relebactam anhydrous, including repackagers and relabelers. The FDA regulates Relebactam anhydrous manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Relebactam anhydrous API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Relebactam anhydrous manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Relebactam anhydrous supplier is an individual or a company that provides Relebactam anhydrous active pharmaceutical ingredient (API) or Relebactam anhydrous finished formulations upon request. The Relebactam anhydrous suppliers may include Relebactam anhydrous API manufacturers, exporters, distributors and traders.
click here to find a list of Relebactam anhydrous suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Relebactam anhydrous as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Relebactam anhydrous API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Relebactam anhydrous as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Relebactam anhydrous and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Relebactam anhydrous NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Relebactam anhydrous suppliers with NDC on PharmaCompass.
Relebactam anhydrous Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Relebactam anhydrous GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Relebactam anhydrous GMP manufacturer or Relebactam anhydrous GMP API supplier for your needs.
A Relebactam anhydrous CoA (Certificate of Analysis) is a formal document that attests to Relebactam anhydrous's compliance with Relebactam anhydrous specifications and serves as a tool for batch-level quality control.
Relebactam anhydrous CoA mostly includes findings from lab analyses of a specific batch. For each Relebactam anhydrous CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Relebactam anhydrous may be tested according to a variety of international standards, such as European Pharmacopoeia (Relebactam anhydrous EP), Relebactam anhydrous JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Relebactam anhydrous USP).
LOOKING FOR A SUPPLIER?